Clinical Trials Logo
  1. Home
  2. Carcinoid Tumors
  3. NCT02795858

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Carcinoid Tumors Clinical Trial

Official title:
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Clinical Trial Summary

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

Clinical Trial Description

This research study is a Phase II clinical trial. The purpose of this study is to test the safety and effectiveness of ramucirumab in advanced, progressive carcinoid tumors. Cancer cells can make growth factors that cause the abnormal growth of new blood vessels. Ramucirumab is an investigational drug which works by blocking a receptor for a vascular growth factor, thereby preventing new blood vessels from forming. This may stop the cancer from growing or spreading and the tumor cells may die. The FDA (the U.S. Food and Drug Administration) has not approved Ramucirumab for treatment of Carcinoid Tumors. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02795858
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date June 14, 2016
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02441062 - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors Phase 2
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT02575300 - Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02441088 - Theranostics: 68GaDOTATOC and 90YDOTATOC Phase 2
Terminated NCT00227136 - Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion Phase 3
Terminated NCT00947167 - A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Phase 2
Terminated NCT02177773 - GA-68 DOTA-TOC of Somatostatin Positive Malignancies Phase 1/Phase 2
Terminated NCT02859064 - Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Phase 2
Active, not recruiting NCT01731925 - A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Phase 2
Completed NCT00088595 - Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Phase 2
Completed NCT01619865 - Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors Phase 1/Phase 2
Completed NCT01253161 - Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) Phase 2
Terminated NCT02359500 - 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) Phase 1
Not yet recruiting NCT01373736 - 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Phase 3
No longer available NCT01980732 - 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors N/A